All In Biotech

Drug Trial Radar · NCT05359211

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Dec 8, 2022

Primary completion

Sep 4, 2025

Study completion Sep 4, 2026

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nektar Therapeutics
First posted
May 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone.

Conditions

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Recurrent Grade 3b Follicular Lymphoma
  • Recurrent Primary Mediastinal Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Refractory Grade 3b Follicular Lymphoma
  • Refractory Primary Mediastinal Large B-Cell Lymphoma
  • Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

  • CyclophosphamideDrug

    Given IV

  • FludarabineDrug

    Given IV

  • Lisocabtagene MaraleucelBiological

    Given IV

  • Polymer-conjugated IL-15 Receptor Agonist NKTR-255Drug

    Given IV

  • X-Ray ImagingProcedure

    Undergo x-ray imaging

  • EchocardiographyProcedure

    Undergo ECHO

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Lumbar PunctureProcedure

    Undergo LP

  • Computed TomographyProcedure

    Undergo PET/CT

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Biospecimen CollectionProcedure

    Undergo blood and CSF sample collection

  • BiopsyProcedure

    Undergo tissue biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated
  2. Dose-limiting toxicity (DLT) ratesTime frame: Up to 21 days after the first NKTR-255 infusion
  3. Optimal biological dose (OBD)Time frame: Up to 12 months after the CAR-T cell infusion
  4. Complete response (CR) rateTime frame: Up to 3 months after the CAR-T cell infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.